HCG is a prescription hormone, and its side-effect profile is best understood through the clinical settings where it is used. This page summarizes commonly discussed effects; it is not medical advice.
The short answer
Almost nothing on HCG's adverse-effect list is caused by the molecule irritating tissue. The effects are downstream consequences of an LH-receptor signal delivered at a dose and time the body did not choose — which is why the profile splits so sharply by who is receiving it. In women undergoing ovarian stimulation the dominant risk is ovarian hyperstimulation syndrome; in men it is the estrogenic and fluid consequences of driving testicular steroidogenesis; in children treated for cryptorchidism it is premature androgen exposure. The labeled reactions and warnings below come from the Pregnyl prescribing information (Pregnyl, DailyMed).
Ovarian hyperstimulation syndrome
The label treats OHSS as a distinct medical event rather than an exaggerated version of ordinary ovarian enlargement, and describes it as capable of progressing rapidly into something serious. The mechanism is a dramatic increase in vascular permeability, which lets fluid accumulate quickly in the peritoneal cavity, the thorax, and potentially the pericardium.
The label names the early warning signs specifically: severe pelvic pain, nausea, vomiting, and weight gain. Its description of severe disease includes hemoconcentration, electrolyte imbalance, ascites, hemoperitoneum, pleural effusion, hydrothorax, acute pulmonary distress, and thromboembolic reactions, along with transient liver function abnormalities. Thromboembolism is explicitly noted as rare and usually associated with severe OHSS.
Two practical points follow. OHSS can develop after gonadotropin treatment has been discontinued, so the risk window outlasts the injection. And the label makes safe ovulation induction conditional on monitoring ovarian response with serum estradiol and transvaginal ultrasound on a regular basis — which is a requirement, not a recommendation. Multiple pregnancy is a further labeled outcome of ovulation induction.
Anaphylaxis is listed separately and specifically for urinary-derived hCG products.
Effects in men
In men the labeled reactions are consistent with what happens when Leydig-cell output is driven upward: the label states that HCG treatment "may sporadically cause gynecomastia," and lists edema and fatigue among reactions attributed to excessive androgen production.
Mechanistically the gynecomastia is an aromatization story. Raising testicular testosterone raises the substrate available for conversion to estradiol, and breast tenderness or tissue growth follows from that ratio rather than from the absolute testosterone number — which is why serum testosterone can look acceptable while the symptom persists. Injection-site pain and rash are also reported.
Because these effects depend on an individual's aromatase activity, baseline hormonal state, and any concurrent testosterone therapy, they are monitored with hormone panels rather than predicted from the dose alone.
Precocious puberty in treated children
The cryptorchidism indication carries its own hazard. Because HCG induces androgen secretion, the label warns it may induce precocious puberty in pediatric patients treated for cryptorchidism, and instructs that therapy be discontinued if signs of precocious puberty appear. This is a direct consequence of the intended mechanism working in a body not developmentally ready for it.
Who the label excludes
The contraindication list is broad and worth reading as a screening requirement rather than a formality. It includes high serum FSH indicating primary gonadal failure in women; uncontrolled non-gonadal endocrinopathies such as thyroid, adrenal, or pituitary disorders; tumors of the hypothalamus or pituitary gland, and of the ovary, breast, or uterus in women or breast or prostate in men; malformations of the reproductive organs incompatible with pregnancy; uterine fibroids incompatible with pregnancy; and abnormal vaginal bleeding of undetermined origin.
The label also states that HCG should be used with gonadotropin therapy only by a physician experienced with infertility problems, and notes that such therapy requires access to appropriate monitoring facilities.
Reading this profile
Two things distort HCG safety discussion online. The first is context collapse: OHSS statistics come from ovarian stimulation cycles and say nothing about a man using HCG alongside testosterone, while gynecomastia data say nothing about IVF. The second is product provenance — assay behavior for hCG is itself variable, with commercial immunoassays differing up to 50-fold between platforms (StatPearls, Human Chorionic Gonadotropin), which is a useful reminder that "HCG" from an unregulated source is not a standardized quantity. The dosing page covers how labeled regimens handle that.
Sport & Anti-Doping Warning
Human chorionic gonadotropin (hCG) has been misused by male athletes as part of steroid cycles to stimulate endogenous testosterone and is specifically prohibited in male competitors.
- >Scientific discussion of hCG misuse and detection in athletes
- >Coverage of recent professional sport suspensions for hCG positives
In anti-doping rules, hCG is banned in males and often treated as a marker of attempted steroid cycle manipulation rather than a benign fertility drug.